NEXTCURE INC (NXTC) Stock Price, Quote, News and Overview
NASDAQ:NXTC - Nasdaq - US65343E1082 - Common Stock - Currency: USD
NXTC Quote, Performance and Key Statistics
NASDAQ:NXTC (2/21/2025, 8:00:01 PM)
0.7229
-0.03 (-3.74%)
The current stock price of NXTC is 0.7229 USD. In the past month the price decreased by -15.75%. In the past year, price decreased by -50.82%.
NXTC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About NXTC
Company Profile
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 82 full-time employees. The company went IPO on 2019-05-09. The firm is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The firm focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.
Company Info
NEXTCURE INC
9000 Virginia Manor Rd Ste 200
Beltsville MARYLAND 20705 US
CEO: Michael Richman
Employees: 82
Company Website: https://www.nextcure.com/
Investor Relations: http://ir.nextcure.com/
Phone: 12403994900
NEXTCURE INC / NXTC FAQ
What is the stock price of NEXTCURE INC today?
The current stock price of NXTC is 0.7229 USD. The price decreased by -3.74% in the last trading session.
What is the ticker symbol for NEXTCURE INC stock?
The exchange symbol of NEXTCURE INC is NXTC and it is listed on the Nasdaq exchange.
On which exchange is NXTC stock listed?
NXTC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEXTCURE INC stock?
8 analysts have analysed NXTC and the average price target is 3.57 USD. This implies a price increase of 393.84% is expected in the next year compared to the current price of 0.7229. Check the NEXTCURE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEXTCURE INC worth?
NEXTCURE INC (NXTC) has a market capitalization of 20.25M USD. This makes NXTC a Nano Cap stock.
How many employees does NEXTCURE INC have?
NEXTCURE INC (NXTC) currently has 82 employees.
What are the support and resistance levels for NEXTCURE INC (NXTC) stock?
NEXTCURE INC (NXTC) has a resistance level at 0.76. Check the full technical report for a detailed analysis of NXTC support and resistance levels.
Should I buy NEXTCURE INC (NXTC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NXTC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NXTC, evaluating the profitability, health, valuation and growth aspects
- NEXTCURE INC (NXTC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEXTCURE INC (NXTC) Sales and EPS estimates to see what analysts future expectations are.
- NEXTCURE INC (NXTC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEXTCURE INC (NXTC) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEXTCURE INC (NXTC) Stock Chart to make your own analysis
- NEXTCURE INC (NXTC) Latest news and press-releases to stay up to date.
Does NEXTCURE INC (NXTC) stock pay dividends?
NXTC does not pay a dividend.
When does NEXTCURE INC (NXTC) report earnings?
NEXTCURE INC (NXTC) will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of NEXTCURE INC (NXTC)?
NEXTCURE INC (NXTC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.09).
What is the Short Interest ratio of NEXTCURE INC (NXTC) stock?
The outstanding short interest for NEXTCURE INC (NXTC) is 0.23% of its float. Check the ownership tab for more information on the NXTC short interest.
NXTC Technical Analysis
NXTC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NXTC. NXTC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NXTC Financial Highlights
Over the last trailing twelve months NXTC reported a non-GAAP Earnings per Share(EPS) of -2.09. The EPS increased by 11.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.77% | ||
| ROE | -77.41% | ||
| Debt/Equity | 0 |
NXTC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to NXTC. The Buy consensus is the average rating of analysts ratings from 8 analysts.